Expert opinion on biological therapy · 2026
Patient-reported satisfaction following a switch from reference denosumab to biosimilar denosumab: real-world data from a Canadian patient survey.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Aliya A, Allard-Chamard Hugues, Kazem Mikameh, Khan Sarah, Ruban Thanu N
Аннотация
BACKGROUND: Following the approval of the first denosumab biosimilar in Canada, patients receiving long-term denosumab treatment for osteoporosis may be switched from the reference biologic to the biosimilar. Supporting patient-reported satisfaction following a switch will be critical to ensure treatment adherence, and foster patient confidence and ongoing acceptance of denosumab biosimilars.
METHODS: This cross-sectional, multicenter, real-world survey in Canada included adults with osteoporosis switched from reference (Prolia®, Amgen) to biosimilar (Jubbonti®, Sandoz) denosumab (n = 435). Data collected included demographics, disease and treatment history, and patient experience and satisfaction with switching. Key endpoints assessed overall satisfaction with the switch (based on a five-point scale) and the perceived importance of economic benefits and improved treatment access.
RESULTS: Most patients (83.1%) expressed satisfaction with the switch, and 84.8% reported being satisfied with the explanation provided about the biosimilar. Clear and adequate communication was significantly associated with overall switch satisfaction (p < 0.001). Better affordability of a biosimilar was considered important by 72.7% of respondents.
CONCLUSION: In this real-world survey, respondents reported high satisfaction with the switch from reference to biosimilar denosumab, particularly when the transition was accompanied by clear communication from their healthcare provider. Findings should be interpreted considering limitations inherent to cross-sectional survey research.
METHODS: This cross-sectional, multicenter, real-world survey in Canada included adults with osteoporosis switched from reference (Prolia®, Amgen) to biosimilar (Jubbonti®, Sandoz) denosumab (n = 435). Data collected included demographics, disease and treatment history, and patient experience and satisfaction with switching. Key endpoints assessed overall satisfaction with the switch (based on a five-point scale) and the perceived importance of economic benefits and improved treatment access.
RESULTS: Most patients (83.1%) expressed satisfaction with the switch, and 84.8% reported being satisfied with the explanation provided about the biosimilar. Clear and adequate communication was significantly associated with overall switch satisfaction (p < 0.001). Better affordability of a biosimilar was considered important by 72.7% of respondents.
CONCLUSION: In this real-world survey, respondents reported high satisfaction with the switch from reference to biosimilar denosumab, particularly when the transition was accompanied by clear communication from their healthcare provider. Findings should be interpreted considering limitations inherent to cross-sectional survey research.